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Background. Human immunodeficiency virus (HIV) transmission among injecting drug users (IDUs) is increasing in the 
United States due to the recent opioid epidemic and is the leading mode of transmission in Eastern Europe.
Methods. To evaluate the overall impact of HIV harm reduction, we combined (1) data from the Swiss HIV Cohort Study and 
public sources with (2) a mathematical model expressed as a system of ordinary differential equations. The model reconstructs the 
national epidemic from the first case in 1980 until 2015. Phylogenetic cluster analysis of HIV-1 pol sequences was used to quantify 
the epidemic spillover from IDUs to the general population.
Results. Overall, harm reduction prevented 15 903 (range, 15 359–16 448) HIV infections among IDUs until the end of 2015, 
5446 acquired immune deficiency syndrome (AIDS) deaths (range, 5142–5752), and a peak HIV prevalence of 50.7%. Introduction 
of harm reduction 2 years earlier could have halved the epidemic, preventing 3161 (range, 822–5499) HIV infections and 1468 
(range, 609–2326) AIDS deaths. Suddenly discontinuing all harm reduction in 2005 would have resulted in outbreak re-emergence 
with 1351 (range, 779–1925) additional HIV cases. Without harm reduction, the estimated additional number of heterosexuals 
infected by HIV-positive IDUs is estimated to have been 2540 (range, 2453–2627), which is equivalent to the total national reported 
incidence among heterosexuals in the period of 2007 to 2015.
Conclusions. Our results suggest that a paramount, population-level impact occurred because of the harm reduction package, 
beyond factors that can be explained by a reduction in risk behavior and a decrease in the number of drug users over time.
Keywords: harm reduction; HIV; injecting drug use; needle and syringe exchange; opioids.
 
Human immunodeficiency virus (HIV) transmission via inject-
ing drug use remains one of the leading modes of transmis-
sion in Eastern Europe and many Asian countries (eg, China, 
Indonesia, Iran), and it is recently re-emerging in the United 
States as a result of the growing heroin epidemic, which is 
driven by overprescription of opioid analgesics [1–3].
Despite a large body of evidence on the effectiveness of harm 
reduction measures to halt the spread of HIV among people who 
inject drugs, there is still a large heterogeneity in the estimates 
[4]. These measures also remain politically controversial and 
are far from being universally implemented and accepted [5, 6]. 
As a result, the harm reduction coverage is still extremely low 
across the world and lags behind World Health Organization 
(WHO) targets [7].
From the early 1980s, Switzerland experienced one of the 
heaviest burdens of drug addiction (mainly heroin and cocaine) 
in Europe, which manifested in the emergence of large open 
drug scenes such as the “Platzspitz” (“Needle-Park”) in Zürich. 
This resulted in an outbreak of HIV, hepatitis B virus (HBV), 
and hepatitis C virus (HCV) infections in this risk group, and 
Switzerland had the highest acquired immune deficiency syn-
drome (AIDS) incidence rate in Europe in 1988 [8]. After a 
growing public outcry, and considering the failure of repressive 
measures as the main response tool, a new progressive drug pol-
icy was gradually implemented that was based on “four pillars”: 
prevention, therapy, harm reduction, and law enforcement [9].
The main harm reduction measures included the follow-
ing: (1) extensive needle-exchange programs, ie, on-site dis-
tribution at open drug scenes, pharmacies, and syringe 
vending machines; (2) supervised drug consumption rooms; 
(3) low-threshold methadone programs; and (4) since 1994, a 
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supervised, injectable medicinal heroin program. In parallel, 
a wide-reaching “STOP AIDS” campaign was launched with a 
tailored message for drug users, which emphasized the HIV risk 
in needle sharing [10]. Furthermore, HIV-infected current and 
former injecting drug users (IDUs) had broad access to anti-
retroviral drug treatment programs [11, 12].
From the public health perspective and particularly regarding 
HIV transmission, those efforts proved to be a phenomenal suc-
cess. Despite a relatively low cessation rate of drug use and des-
pite the fact that the prevalence of heroin addiction remained 
relatively stable [13], the transmission of HIV among IDUs in 
Switzerland dropped from a peak of 937 new cases in 1989 to a 
low of 2% (9 of 519) of all new infections in 2014, hence almost 
eliminating HIV transmission among IDUs.
To date, a quantitative evaluation of the cumulative impact of 
the implemented harm reduction measures has not been per-
formed. In this study, we combine a mathematical model with 
the data from the Swiss HIV Cohort Study (SHCS), the SHCS 
drug-resistance sequence database, national epidemiological 
data, and data from previous works to perform the following: 
(1) estimate the counterfactual HIV incidence and prevalence 
among IDUs in absence, or with delayed introduction, of the 
harm reduction measures; (2) examine the effect of discontin-
uing harm reduction measures when the HIV epidemic among 
IDUs appears as under control; and (3) estimate the cumulative 
effect of the implemented harm reduction measures on the spill-
over of the epidemic to the general population in Switzerland.
METHODS
Ethics
We obtained ethical approval from the SHCS and written 
informed consent from all participants.
Swiss HIV Cohort Study and the Drug Resistance Database
The SHCS is an ongoing prospective cohort of HIV-positive 
individuals. The study prospectively enrolled patients since 
1988, and some data were retrospectively ascertained until 
1981. During the biannual outpatient visits, comprehensive 
clinical and behavioral data are collected [14]. In addition, for 
more than 60% of the participants, partial pol sequences are 
available. The representativeness of the SHCS was estimated to 
be high, with good coverage of marginalized and hard-to-reach 
populations, and is particularly good for subtype B, which is the 
predominant subtype in Switzerland [15].
Mathematical Model
We constructed a compartmental, deterministic transmis-
sion model represented as a nonlinear system of 32 ordinary 
differential equations (Figure  1). The model reconstructs the 
epidemic from the first introduced HIV case into the IDUs pop-
ulation in 1980 and is numerically solved until 2015. The mod-
eled population corresponds to all heroin users in Switzerland. 
The model is divided into 3 meta-strata that represent a typical 
progression of an addiction course: (1) “non-injectors” repre-
sent people who smoke or snort heroin; (2) “active injectors” 
represent populations at risk of infection with HIV by sharing 
injection paraphernalia; and (3) “past-injectors” represent peo-
ple covered by harm reduction that are still addicted to opioids, 
but do not contribute to the infectious pool anymore, since they 
switched to snorting/smoking or are in a methadone or super-
vised heroin program and permanently ceased injecting in a 
setting that facilitates transmission. The active injectors and the 
past-injectors are stratified into HIV susceptible and infected. 
All infected IDUs start in the undiagnosed compartment and 
can be diagnosed either in recent, chronic, or AIDS stage, with 
different rates. Since 1996, diagnosed individuals can transit 
to a combined antiretroviral treatment (cART) treated stage, 
with rates that depend on the disease stage and are increasing 
with calendar year to reflect transition to immediate treatment. 
Those rates were estimated from the SHCS based on CD4 
counts as a proxy for disease stage (Supplementary Table  3). 
Except for past-injectors, which are covered by harm reduction 
by definition, each compartment is mirrored by a parallel harm 
reduction-covered strata to which individuals transit with an 
average rate that represents the harm reduction recruitment 
rate. Because the different harm reduction layers were overlap-
ping in time (see Supplementary Figure 1), we do not model the 
separate effect of each measure (methadone, needle exchange, 
supervised injectable heroin, etc), but we use a harm reduc-
tion “package” [7] that was introduced in 1988, which means 
being covered by any of the harm reduction measures versus 
being missed by all of them. The exception to this pooled con-
sideration of harm reduction is the restricted methadone pro-
gram, because this was the main available measure before the 
introduction of the package, which allowed us to disentangle 
its effect. We assumed that IDUs covered by harm reduction 
had lower HIV transmission coefficient. This transmission rate, 
the harm reduction package recruitment rate, and other model 
parameters were determined by fitting the model using negative 
log-likelihood-distributed error to the annual number of new 
HIV cases and AIDS deaths in IDUs that were reported to the 
Swiss Federal Office of Public Health. See the Supplementary 
Data for a detailed description of the model, parametrization, 
and sensitivity analysis.
Phylogenetic Analysis
A large maximum likelihood phylogenetic tree with 19 604 Swiss 
sequences and 90 994 non-Swiss background sequences was 
constructed as previously described [16]. Introduction events 
into the general (heterosexual) population that originated from 
IDUs were detected by extracting all clusters that comprised 
only Swiss sequences and had at least 1 IDU and 1 heterosexual 
individual. For each IDU, the tree nodes were traversed back 
until the cluster either contained another IDU individual or a 
risk group that is other than an IDU or heterosexual, then the 
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largest previous cluster was returned. This way, our analysis 
estimated not only the spillover population but also the further 
transmission of HIV within the heterosexual population caused 
by that spillover population. See the Supplementary Data for 
a detailed description of cluster analysis and the spillover 
calculation.
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Figure 1. Graphical representation of the mathematical model. I, infected; S, susceptible; T, treated with cART (since 1996).
4 • OFID • Marzel et al
Analysis Tools
Statistical analysis was performed with R (version 3.2.3). The 
system of equations was solved using the package deSolve (ver-
sion 1.14); the package “ape” (version 4.1) was used for phyloge-
netic analysis.
RESULTS
Injecting Drug Users in the Swiss HIV Cohort Study
Between 1983 and 2016, 4806 IDUs were enrolled in the SHCS, 
3311 of those were most likely infected with HIV through shar-
ing infected paraphernalia, and the remaining 1495 might have 
been infected via sharing or via sexual route.
The number of newly enrolled IDUs decreased with time from 
553 newly registered in 1990, to 17 in 2016 (P for trend <.0001; 
Figure  2), hence accurately reflecting the drop of HIV incidence 
among IDUs in Switzerland [17]. Most IDUs were men (65.7%, 3157 
of 4806; Supplementary Table 1) and were without university edu-
cation (99.1%, 4761 of 4806). Both time to cART and subsequently 
the fraction of IDUs with AIDS-defining illness have decreased with 
time (P for trend .048), with almost immediate treatment initiation 
in 2010–2016, and 15.9% (11 of 69) of IDUs with AIDS-defining 
illness, compared with 48.0% (1441 of 2999)  for IDUs that were 
diagnosed until 1990 (Fisher’s exact test, P < .0001).
The period prevalence of HBV and HCV coinfections was 
high, with 78.3% (2312 of 2954; 1862 not tested) and 94.6% (2728 
of 2883; 1923 not tested), respectively, for the entire period, and 
58.2% (39 of 67; 2 not tested) and 73.1% (49 of 67; 2 not tested) 
in the last 7 years. This high prevalence of HBV and HCV alludes 
to a high fraction of nonassortative needle sharing, as expected 
in an open drug scene and assumed in our model.
Model Performance
The proposed model exhibits a qualitatively good fit, both to the 
annual number of newly diagnosed HIV cases among IDUs in 
Switzerland and to the annual number of reported AIDS deaths 
(Figure 3a and b, respectively). The model also catches, for the 
most part, the assumed dynamic of the population of prob-
lematic heroin users in Switzerland, with a peak during early 
1990s and a subsequent gradual decline (Figure 3c). Finally, the 
model predicts HIV prevalence among IDUs in Switzerland, 
which falls in line with published estimates of approximately 
10% between 1993 to 2000 [18]. Human immunodeficiency 
virus prevalence and the number of heroin users were deliber-
ately not used for model fitting, to serve as an additional quality 
check for the prudence of our model; nevertheless, the dynam-
ics of those compartments is captured well by the model.
The Combined Effect of Harm Reduction Measures, No Harm Reduction, 
and Sudden Discontinuation
First, we examined the extreme—yet relevant to other coun-
tries—worst-case scenario of no harm reduction at all since 
1980, which required transferring the individuals on restricted 
methadone—that was available since late 1970s—to model 
compartments not covered by any harm reduction, from the 
start of the simulation. This resulted in 15 903 (range, 15 359–
16 448) additional infections until the end of 2015 (Figure 4a 
and Figure  5), 5446 new additional AIDS deaths (range, 
5142–5752) (Figure 4b), and a peak HIV prevalence of 50.7% 
(Figure 4c). Next, we examined whether a sudden discontinu-
ation of all harm reduction services, after several years of low 
incidence, will result in a renewed outbreak. Our model shows 
that suddenly discontinuing all harm reduction in the year 2000 
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(10 years after the incidence peak) or 2005 would have resulted 
in outbreak re-emergence up to 2015 in both scenarios, with 
4965 (range, 3420–6511) and 1351 (range, 779–1925) additional 
HIV cases, respectively (Figure 4a and Figure 5). However, the 
re-emergence rate is twice as slow when harm reduction is 
discontinued in 2005 compared with 2000, with linear slopes 
of 20.2 (95% confidence interval [CI], 18.8–21.6) and 40.5 (95% 
CI, 39.6–41.3) new cases, respectively, for the first 5 years after 
discontinuation. Because of immediate cART in the recent 
years, discontinuation in 2005 would have had limited to no 
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effect on the number of AIDS deaths with 153 (range, 101–206) 
additional deaths (Figure 4b).
Delayed or Earlier Introduction
A delay of 2  years in the introduction of the harm reduc-
tion package, ie, 1990 instead of 1988, would have resulted in 
2325 (range, 1580–3071) additional HIV cases (Figure 4e and 
Figure  5) and 971 additional AIDS deaths (range, 724–1219) 
(Figure 4f). On the other hand, a 2 years earlier introduction 
(ie, 1986)  could have halved the epidemic, preventing 3161 
(range, 822–5499) HIV infections and 1468 (609–2326) AIDS 
deaths, with a peak HIV prevalence among IDUs that would 
have never exceeded 11.3 % (range, 8.5%–15.3%).
Only Restricted Methadone and No New Recruitment Since 2000
Next, we examined the effect of not introducing the extensive 
harm reduction package but continuing with high-thresh-
old methadone only, with the same recruitment rate as before 
1988 (~8.5% per year; Supplementary Data). This would have 
resulted in 11 462 additional HIV cases (range, 10 399–12 526) 
(Figure  4i and Figure  5) and 3190 (range, 2793–3588) add-
itional AIDS deaths (Figure  4j). It is notable that restricted 
methadone is still superior to the scenario with no harm reduc-
tion at all, with 4441 prevented cases and 2256 fewer deaths. 
Finally, we explored a less radical discontinuation scenario, in 
which individuals that are covered by harm reduction remain 
in the covered compartment (with the same dropout rate); 
however, since 2000, there is no new recruitment to the harm 
reduction covered compartments. This scenario emulates a 
harm reduction budget cut plot. This would have resulted in 
a slow re-emergence with 1616 additional HIV cases (range, 
938–2295) (Figure 4i) with no substantial increase in additional 
AIDS deaths (range, 114–235) (Figure 4j).
The Effect of Combined Antiretroviral Treatment 
Although, chronologically, the epidemic reached its peak and 
began to decline before cART introduction in 1996, we still 
observe a moderate protective effect of cART (the harm reduc-
tion-related parameters were not changed in this scenario), 
with 771 (range, 401–1142) new HIV cases prevented by cART 
alone until the end of 2015, and—as expected—an ample effect 
on AIDS deaths, with 1771 (range, 991–2552) prevented deaths 
(Figure 5 and Supplementary Figure 3).
Spillover to the General Population
The phylogeny contained 4235 sequences from 2399 SHCS 
IDUs, with 94.3% (2262 of 2399) harboring subtype B. Cluster 
analysis showed 499 heterosexuals clustered with IDU in Swiss-
only clusters, which were linked to 358 putative cross-risk-
group introduction events (Supplementary Figure 4) in which 
the phylogenetically closest IDU was male in 60.3% (216 of 
358) and female in 39.7% (142 of 358). In absence of any harm 
reduction (scenario a), the estimated additional number of het-
erosexuals whose infection originated from HIV-positive IDUs 
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is estimated to have been 2540 (range, 2453–2627) new infec-
tions, which is comparable to the total national HIV incidence 
among heterosexuals in the entire period from 2007 to 2015 
(n = 2476, Federal Office of Public Health [19–21]).
DISCUSSION
According to UNAIDS, in Eastern Europe and Central Asia, 51% 
of all newly diagnosed HIV is attributed to people who inject 
drugs [22]. However, only 7% to 15% of all IDUs in Eastern 
Europe have access to needle and syringe programs, whereas 
for opioid substitution treatment the coverage is approximately 
1% [3], and it remains illegal in Russia. Likewise, the Western-
Europe, North-America, and Australasia region combined have 
not yet reached the WHO middle-coverage target of 20% for 
needle and syringe programs [7].
Our model estimates that a very high prevalence of HIV 
(~50%) among IDUs would have occurred in the absence 
of harm reduction. More importantly, our model takes into 
account both the overall decrease in heroin consumption as 
well as the decreasing number of injectors. Thus, the high prev-
alence in the absence of harm reduction is predicted to have 
occurred despite those general trends of drug use. This coun-
terfactual estimate is also in line with historical seroprevalence 
data from socioeconomically comparable areas that had little to 
no harm reduction at that time. Frankfurt, Germany, had a large 
open drug scene, with HIV prevalence of 73.7% in 1994 [23], 
in Spain the prevalence was 63% in 1996 [24], and in northern 
Italy the prevalence was 49% in 1989 [25]. Some areas in the 
United States also exhibited high HIV prevalence, with 61% in 
New York [26] and 60% in New Haven, Connecticut [27], dur-
ing the early 1990s. In Eastern Europe, and especially in Russia, 
which exercises a repressive approach toward IDUs and repul-
sion of the harm reduction concept on the political level, a 37% 
prevalence was estimated in 2003 [3]. In Estonia, the rate was as 
high as 72% [3].
Considering the low incidence of HIV among IDUs in 
Switzerland in the recent years, there is a growing debate on 
whether the funds invested in harm reduction can be safely allo-
cated elsewhere. In 2016, the canton of Zürich decided to cut 4.5 
million Swiss Francs from the drug-addiction treatment pro-
grams until 2019 [28]. Our study shows that suddenly stopping 
harm reduction measures, even several years after the epidemic 
appears as under control, can lead to a new outbreak. This result 
is supported by a recent experience from Greece, a country with 
a historically low HIV incidence among IDUs (1.5% to 4.5% of 
all new infections during 2000–2010) [29]. In 2011, due to the 
fiscal crisis and severe austerity, the harm reduction measures 
were underperforming [30]. Until the first 8 months of 2013, 
1000 new HIV cases among IDUs have already been diagnosed 
[31]. After harm reduction—in form of needle and syringe 
exchange and opioid-substitution—was scaled up again, HIV 
incidence was reduced 5-fold within 1 year [32].
Our estimates show a moderate impact of cART on curb-
ing HIV transmission among IDU in Switzerland. This can be 
attributed to 2 factors: (1) cART was introduced in 1996 after the 
epidemic was already contained by the harm reduction meas-
ures, which started in part in 1988; and (2) the effect of cART 
is partly undermined by lower adherence among IDUs [33], 
which was also reflected in our model. However, as expected, 
cART prevented a large number of AIDS deaths among IDUs.
Our model has several benefits and can be adjusted for the 
following factors: (1) the decrease in the number of injectors 
with time; (2) the possible reduction in risk behavior even in 
people who are not reached by any harm reduction due to over-
all awareness of HIV [34]; and (3) the decrease in needle shar-
ing by IDUs who are aware of their HIV-seropositive status and 
are concerned of infecting others [35]. Because the extent of the 
relevance of those developments to the Swiss settings is uncer-
tain, we speculate that we might have underestimated the effect-
iveness of the combined harm reduction measures and that our 
estimates lay on the conservative side. This is further supported 
by the fact that, due to scarcity of data, we could not account 
for cocaine-only injectors; however, injectors of cocaine and 
heroin (“Speedball”) were accounted for in our model. In add-
ition, our model has the advantage of being applicable to the 
current opioid analgesics-driven HIV epidemic, because it 
accounts for the transition from a noninjecting to injecting 
drug administration mode.
Our model is limited because it does not differentiate 
between the different measures implemented, except for 
restricted methadone. However, in this work, we were a pri-
ori interested in cumulative estimates. Our model also only 
accounts for sexual transmission within but not between the 3 
meta-strata. Nonetheless, the contribution of sexual transmis-
sion is expected to be of secondary importance due to an 8-fold 
higher per-act transmission probability for needle sharing [36]. 
Finally, as it is often in modeling studies, the uncertainty ranges 
of our predictions might be underestimated.
Indeed, not all countries affected by an HIV epidemic among 
IDUs possess the resources that were available in Switzerland. 
However, the unit costs of harm reduction interventions are rel-
atively low and are estimated to be highly cost effective [7] and, 
in light of the results presented here, might even be cost saving. 
In addition, we demonstrated that the benefits of harm reduc-
tion extend beyond the population of IDUs, with thousands of 
averted spillover heterosexual infections. Similar studies are 
needed for the HCV epidemic, which affects this population 
even more severely than HIV.
CONCLUSIONS
In summary, our results highlight, based on the Swiss experi-
ence, the pivotal role of harm reduction for successful curb-
ing of HIV transmission among IDUs and prevention of grave 
repercussions for the general population.
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Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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